



8th July 2026

Subject: Response to your letter dated 24 June 2026

Dear Ms. Strinnholm and Ms. Ihrlund,

We acknowledge receipt of your letter dated 24 June 2026 concerning certain promotional materials displayed at the BeOne booth during the EHA Congress in Stockholm.

Following the discussion that took place on 14 June 2026, BeOne decided, as a matter of good faith and in the interest of avoiding an unnecessary dispute, to remove the materials from display on the same day, and not on the day after as incorrectly stated in your letter.

For the avoidance of doubt, BeOne does not accept the factual or legal assertions set out in your letter, including your characterization that the materials violated the LER or that BeOne accepted AstraZeneca's cease-and-desist request. The removal of the materials was a voluntary decision taken without prejudice to BeOne's position and does not constitute an admission of liability, non-compliance, or wrongdoing of any kind.

Accordingly, BeOne also does not agree with the statement in your letter that it "accepted AstraZeneca's cease-and-desist request."

With respect to your request that BeOne confirm that the materials and/or the underlying claims will not be used in the future, BeOne is not in a position to provide such an undertaking. BeOne reserves all of its rights to use scientific and promotional materials, including claims supported by the available evidence, where and to the extent such use is permissible under the applicable laws, regulations and industry codes in the relevant jurisdiction.

We trust this clarifies BeOne's position.

Yours sincerely,

Martin Skovgaard Larsen

Signed by:

A handwritten signature in black ink that reads 'Martin Skovgaard Larsen'.

952BAD0E1368492

Martin Skovgaard Larsen

Compliance Lead

Catalyze Cluster, Incubator Cluster and UK & Ireland



BeOne Medicines GmbH (formerly BeiGene International GmbH)
Aeschengraben 27
CH-4051 Basel, Switzerland – Remote

martinskovgaard.larsen@beonemed.com

Phone: **+45 24 66 43 48**

